SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High – Time to Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $27.05 and last traded at $23.4350, with a volume of 20,998,041 shares. The stock had previously closed at $7.47.

Top SELLAS Life Sciences Group Stories

These are some of the SLS stories that stood out recently:

  • Positive Sentiment: SELLAS said galinpepimut-S (GPS) met the primary endpoint in the REGAL trial in certain patients with acute myeloid leukemia (AML). GPS reduced the risk of death by 41%; median overall survival was 24.0 months versus 14.7 months with best available treatment (hazard ratio 0.59; p=0.035). SELLAS REGAL trial results
  • Positive Sentiment: The company plans to discuss an accelerated filing strategy with the FDA and is preparing for a Biologics License Application submission in the first half of 2027. GPS was generally well tolerated, with no new safety signals reported. GPS trial results and planned FDA filing
  • Neutral Sentiment: Trading in SLS was temporarily paused for news and later for a Limit Up-Limit Down (LULD) pause, indicating unusually volatile trading around the announcement.

Analysts Set New Price Targets

SLS has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Check Out Our Latest Analysis on SELLAS Life Sciences Group

SELLAS Life Sciences Group Stock Performance

The stock has a market cap of $3.68 billion, a price-to-earnings ratio of -88.28 and a beta of 2.73. The business has a 50-day simple moving average of $10.90 and a two-hundred day simple moving average of $8.79.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05).

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of large investors have recently modified their holdings of the business. Dagco Inc. grew its position in shares of SELLAS Life Sciences Group by 8.4% in the 3rd quarter. Dagco Inc. now owns 1,336,449 shares of the company’s stock valued at $16,452,000 after acquiring an additional 104,016 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of SELLAS Life Sciences Group by 86.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,088,136 shares of the company’s stock valued at $13,395,000 after purchasing an additional 503,101 shares during the period. Bank of America Corp DE raised its holdings in shares of SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the period. Wellington Management Group LLP lifted its stake in SELLAS Life Sciences Group by 73.2% in the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at about $7,823,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Recommended Stories

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.